How much revenue does Zhejiang Hisun Pharmaceutical make?

Zhejiang Hisun Pharmaceutical reported 9.79 billion CNY in revenue for fiscal year 2024, down 5.7% from 10.37 billion CNY in fiscal year 2023. In Q2 2025 revenue was 2.62 billion CNY.

What is Zhejiang Hisun Pharmaceutical's largest business segment?

Pharmaceutical Manufacturing, with 6.50 billion CNY or 62% of segment revenue in fiscal year 2025. Next: Pharmaceutical Business (37%) and Others (under 1%).

Where does Zhejiang Hisun Pharmaceutical make most of its revenue?

China: 94% of revenue by region in fiscal year 2025, followed by Foreign (6%).

What companies are similar to Zhejiang Hisun Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Joincare Pharmaceutical Group Industry Co.,Ltd. (600380.SS), ApicHope Pharmaceutical Group Co., Ltd. (300723.SZ), Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ), Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ).

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) Stock

About Zhejiang Hisun Pharmaceutical Co., Ltd.

Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients. It also offers its products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedics treatment; nutrition and healthcare; and oncology, ADC small mole...

At a glance

Zhejiang Hisun Pharmaceutical reported revenue of 9.79 billion CNY for fiscal year 2024, down 5.7% from fiscal year 2023, and net income of 601.18 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 2.62 billion CNY, up 4.0% from a year before. Its largest business segment, Pharmaceutical Manufacturing, brought in 62% of segment revenue in fiscal year 2025; China was the largest region with 94%.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.